title: [A prospective, observational, all-prescribed-patients study of cyclosporine 0.1% ophthalmic solution in the treatment of vernal keratoconjunctivitis].
abstract: OBJECTIVE
  To evaluate the effectiveness and safety of topical cyclosporine 0.1% in patients with vernal keratoconjunctivitis (VKC).
  
  
  METHODS
  All patients who were prescribed topical cyclosporine 0.1% during the 2 year period after market launch were registered and followed up for 6 months. We assessed the severity of 6 subjective ocular symptoms, such as itching and 10 objective signs, such as giant papillae in the tarsal conjunctiva.
  
  
  RESULTS
  All scores for symptoms and signs in 2597 patients with VKC significantly decreased throughout a 6-month follow-up. For total symptoms scores, mean changes from baseline at 1, 3, and 6 months were -4.0, -4.8, and -5.1, respectively. Total sign scores were -4.6, -6.1, and -6.5, respectively. Thirty percent of topical steroid users were able to discontinue the steroids within 3 months. Adverse drug reactions (ADRs) were found in 7.44% of patients, the most common ADR being eye irritation. Ocular infections were observed in 1.44% of patients. During long-term use of topical cyclosporine 0.1%, there was no increase in the incidence of ADR and no late-onset ADRs.
  
  
  CONCLUSIONS
  Topical cyclosporine 0.1% is an effective and safe treatment for VKC over the long term, provided care is exercised to avoid the occurrence of infection.
authors: Department of Ophthalmology, Tokyo Women's Medical University, School of Medicine, Tokyo, Japan. takamura@oph.twmu.ac.jp
authors: Etsuko
authors: E
authors: Takamura
authors: Eiichi
authors: E
authors: Uchio
authors: Nobuyuki
authors: N
authors: Ebihara
authors: Shigeki
authors: S
authors: Okamoto
authors: Naoki
authors: N
authors: Kumagai
authors: Jun
authors: J
authors: Shoji
authors: Yayoi
authors: Y
authors: Nakagawa
authors: Kenichi
authors: K
authors: Namba
authors: Atsuki
authors: A
authors: Fukushima
authors: Hiroshi
authors: H
authors: Fujishima
authors: Dai
authors: D
authors: Miyazaki
authors: Yuichi
authors: Y
authors: Ohashi
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D002648:Child; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D016572:Cyclosporine / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D009883:Ophthalmic Solutions; D011446:Prospective Studies
chemical_list: D009883:Ophthalmic Solutions; D016572:Cyclosporine